Effects of ASKP1240 Combined With Tacrolimus or Mycophenolate Mofetil on Renal Allograft Survival in Cynomolgus Monkeys
Authors:
Open Access
- 15 August 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 98 (3) , 267-276
Abstract
Background Blocking the CD40-CD154 signal pathway has previously shown promise as a strategy to prevent allograft rejection. In this study, the efficacy of a novel fully human anti-CD40 monoclonal antibody—ASKP1240, administered as a monotherapy or combination therapy (subtherapeutic dose of tacrolimus or mycophenolate mofetil), on the prevention of renal allograft rejection was evaluated in Cynomolgus monkeys. Methods Heterotopic kidney transplants were performed in ABO-compatible, stimulation index 2.5 or higher in the two-way mixed lymphocyte reaction monkey pairs. Animals were divided into 12 groups and observed for a maximum of 180 days. Histopathologic, hematology, and biochemistry analyses were conducted in all groups. Cytokine release (interleukin [IL]-2, IL-4, IL-5, IL-6, tumor necrosis factor, and interferon-γ) was investigated in several groups. Results ASKP1240 prolonged renal allograft survival in a dose-dependent manner in monotherapy. Low-dose (2 mg/kg) or high-dose (5 mg/kg) ASKP1240, in combination with mycophenolate mofetil (15 mg/kg) or tacrolimus (1 mg/kg), showed a significantly longer allograft survival time compared with monotherapy groups. No obvious side effects including drug-related thromboembolic complications were found. Cytokine release was not induced by ASKP1240 administration. Conclusion The present study indicates that ASKP1240, alone or in combination with other immunosuppressive drugs, could be a promising antirejection agent in organ transplantation.Keywords
This publication has 37 references indexed in Scilit:
- CD40 Blockade Combines with CTLA4Ig and Sirolimus to Produce Mixed Chimerism in an MHC-Defined Rhesus Macaque Transplant ModelAmerican Journal of Transplantation, 2011
- Nondepleting Anti-CD40-Based Therapy Prolongs Allograft Survival in Nonhuman PrimatesAmerican Journal of Transplantation, 2011
- A Human Anti-CD40 Monoclonal Antibody, 4D11, for Kidney Transplantation in Cynomolgus Monkeys: Induction and Maintenance TherapyAmerican Journal of Transplantation, 2009
- Promises and Obstacles for the Blockade of CD40–CD40L Interactions in AllotransplantationTransplantation, 2008
- IntroductionClinical Transplantation, 2008
- A Novel Fully Human Anti-CD40 Monoclonal Antibody, 4D11, for Kidney Transplantation in Cynomolgus MonkeysTransplantation, 2007
- The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockadeBlood, 2003
- Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primatesTransplantation, 2003
- Anti-CD40 therapy extends renal allograft survival in rhesus macaques1Transplantation, 2002
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999